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Abstract
Background: Transference of reference intervals (RIs) from 
multicentre studies are often verified by use of a small 
number of samples from reference individuals or by the 
use of one serum sample (Serum X for NORIP RI). Despite 
recommended and appropriate methods, both have incon-
veniencies and drawbacks. Several attempts have been 
made to develop an indirect method, which uses historical 
data from the laboratory. These methods are retrospective 
relying on older test results. A near prospective method 
would be preferable for the laboratories introducing new 
methods or changing analytical platforms.
Methods: We performed a data mining experiment using 
results from our laboratory information system covering 
patients from a large geographic area. Request patterns 
for patients with assumed healthy characteristics were 
identified and used to extract laboratory results for calcu-
lation of new RI by an indirect method. Calculated RI and 
confidence intervals (CIs) were compared to transferred 
NORIP RI verified by NFKK Reference Serum X.
Results: We found that our indirect method and NFKK 
Reference Serum X in general produced similar results 
when verifying transference of RI. The method produces 
results for all stratifications. Only single stratifications 
and one analyte showed unexplained incongruences to 
the NORIP RI.
Conclusions: Our results suggest using request patterns as 
a surrogate measure for good health status. This allows for 
a data mining method for validation of RI or validating their 
transference, which is likely to be applicable in countries 
with similar healthcare and laboratory information system.
Keywords: data mining; indirect; NORIP; reference inter-
val; transference; validation.
Introduction
The availability and use of reference intervals (RIs) from 
large multicentre studies supports mobility of patients 
between hospitals and regions. The individual clinical 
biochemistry laboratory also benefits from multicentre 
studies as they might transfer these RIs instead of estab-
lishing local RIs, a task beyond the scope of most labo-
ratories. The common method according to (EP28-A3C) 
published by the Clinical and Laboratory Standards 
Institute (CLSI) and International Federation of Clinical 
Chemistry and Laboratory Medicine (IFCC) recommends 
transference of RIs to be verified by ≥20 reference individ-
uals from the laboratory’s own healthy subject population 
[1–3]. The Nordic Reference Interval Project 2000 (NORIP) 
uses a different approach that relies on analysis of a 
single reference serum specimen NFKK Reference Serum 
X (Serum X). The Serum X results allow for assessing bias 
for the laboratory methods. If specified bias goals are 
met, NORIP RIs can be implemented [4]. Both the CLSI/
IFCC and the Serum X methods have known issues. For 
the CLSI/IFCC method, the laboratory still has to identify 
reference individuals, and result evaluation makes it pos-
sible to oversee a clinical relevant bias due to power prob-
lems or accepting too wide RIs. The Serum X approach 
estimates bias at a single level only although bias often 
differs over the measuring range, which has to be some-
what subjectively accounted for, e.g. by inspecting data 
combined with general knowledge about methods in 
use. Theoretically, the CLSI/IFCC and the Serum X-based 
methods could lead to false acceptance or rejection of RI 
transference. This poses uncertainties when attempting 
RI transfer. Although difficult to develop, more objective 
and robust methods would be very preferable. Recently, 
via data mining methods, several comparisons have been 
made between the direct method for establishing RIs and 
the indirect method [5–9]. The indirect method makes use 
of patient data stored in laboratory information systems 
(LIS). A typical method assumes that individuals with good 
health have infrequent contact to healthcare. Infrequent 
contact is derived by counting the number of requested 
laboratory tests. These methods extract test results from 
individuals with a low number of test requests in pre-
ceding and following years. Unfortunately, the included 
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results are therefore not necessarily contemporary. This 
makes the methods less suitable for transference of RIs 
to present methods. A near prospective method would be 
preferable, for instance, when introducing new methods 
with RI supplied by the manufacturers or when changing 
analytical platforms. In the present study, we investigate 
a near prospective indirect method based on data mining 
an LIS for individuals with an apparent low indication 
for biochemistry investigations. The laboratory’s healthy 
subject population was sampled from the outpatient 
population using a single selection criteria. Indirect RIs 
are calculated as 2.5th and 97.5th percentile with the non-
parametric approach after proper selection of the suitable 
assumed healthy individuals. The obtained RIs are com-
pared with NORIP RIs and Serum X verification.
Materials and methods
Data sets
In 2016, the laboratory performed around 8.5 million tests covering 
around 70% of the yearly requests for biochemical testing in the 
regional LIS database. As the LIS covers a large geographical area, all 
biochemical contacts to healthcare can be assumed to be registered 
in the LIS. Biochemical test are requested by hospitals, general prac-
titioners and medical specialists. Approximately half of the overall 
test requests were on outpatients.
Analysis of request pattern
From a data set of outpatient results in the period of (01.04.2017–
31.05.2017), all unique requests were identified. The time between 
these requests and the previous request on the patients was calcu-
lated and designated time to previous request (TTPR) (Figure 1). If no 
previous request was found we assigned a value of >24 months. For 
each month, we visualised the number of results and calculated the 
percentage of test results within their respective reference interval 
(Figure 2).
Analysis of NFKK reference Serum X
Serum X was analysed according to the manufacturer’s instructions, 
without investigating for correction [4, 10]. Briefly, 10 measurements 
of each analyte were performed in one analytical run, including con-
trols before and after the analytical run. Results were analysed for 







18 m24 m TTPR
Figure 1: Diagram outlining the inclusion criteria and calculation of 
TTPR.
Four different possible request patterns are shown. Red box indicate 
sampling time. Tubes indicate requests for biochemical testing. 
Black dashed lines indicate calculated TTPR. Green dashed lines 
indicate TTPR 18 and 24 months, respectively.
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Figure 2: General analysis of request pattern.
(A) Number of patients identified in each interval of TTPR. 
(B)  Percentage of patient results in each interval of TTPR 
falling within the NORIP RIs. Blue is combined results for all 
tests. The red curve is albumin results and creatinine results are 
green.
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Indirect RI determination
Patient results were extracted from the LIS using methods similar to pre-
vious published methods [6–8]. Included test results were all analysed 
at Aalborg University Hospital in the period of (26.03.2017–02.06.2017). 
Plasma samples from general practitioners were either collected in our 
outpatient clinic or delivered from the general practitioners by land 
transport held at 21 °C. The following inclusion criteria’s were used:
 – Each unique patient had only one request for biochemical testing 
in the regional LIS within 18 months retrospective of an included 
sample. This criterion ensured exclusion of patients undergoing 
yearly controls and thus focusing the included results on indi-
viduals with limited indication for biochemical testing;
 – Furthermore, the data retrieved from the LIS database are all 
from outpatients consulting general practitioners and not from 
other medical specialists or hospital departments. These outpa-
tients constitute the laboratory’s subpopulation with the lowest 
percentage of diseased subjects.
Biochemical analysis
All tests were analysed in a routine clinical biochemistry laboratory 
on c502/c702/e602 Cobas 8000 clinical chemistry and immunochem-
istry modules (Roche Diagnostics A/S, Hvidovre, Denmark), except 
LDL-cholesterol, which was calculated with Friedewalds formula [12].
Calculation of RIs
Calculations, statistical evaluations, graphical representations and 
simulations were made in Rstudio (Version 1.0.136  with R Version 
3.3.2). Tukey’s fence was used for defining and removing outliers 
as described by Horn et al. [2, 13]. Tukey’s fence is defined by 1st 
quartile–1.5 × (3rd quartile–1st quartile) and 3rd quartile + 1.5 × (3rd 
quartile–1st quartile). Data were visualised in histograms and Q-Q 
plots for evaluating the validity of outlier definition and possible 
transformation.
The results were evaluated in three groups:
 – Stratifications with <60 results after outlier removal. The 
remaining results are evaluated according to % of results above 
NORIP upper limit (% AUL) and % of results under NORIP lower 
limit (% ULL). This group includes urea.
 – Stratifications with ≥60 results after outlier removal and data 
assumes a normal distribution. The remaining results are evalu-
ated for % AUL and % ULL. RI limits are calculated as well as a 
90% confidence interval (CI).
 – Stratifications with ≥60 results and data are not normal distrib-
uted. Results are transformed with natural logarithm and outliers 
are removed. The remaining results are evaluated for % AUL and 
% ULL and used to calculate a RI with CI. This group includes ala-
nine transaminase; alkaline phosphatase; amylase, pancreatic; 
bilirubin; creatinekinase; γ-glutamyltransferase; and triglyceride.
The 95% RI limits were evaluated with non-parametric methods 
(2.5% and 97.5% percentiles) on the population/transformed popu-
lation without outliers. The 90% CIs of the limits were calculated 
by bootstrap resampling with replacement as described in [14, 15]. 
Per distribution, 500 resamplings were made and RI limits were 
determined for all 500 resamplings. From these RI limits, the 5% and 
95% percentile constitute the 90% CI of the RI [15].
Accept criteria for transfer of RIs
A validation of transference of the NORIP RI was considered accepted 
based on the following criteria:
 – NORIP limit is within CI of indirect limit.
 – Accept criteria based on desirable performance related to bio-
logical variation [16]. In total, between 0% and 6% of patient 
results without outliers are allowed outside the NORIP limits 
(sum of % ULL and % AUL). To make sure the distribution is 
not too biased, a maximum difference of 3% is allowed (differ-
ence between % ULL and % AUL). This allows for a maximum of 
4.5% outside one RI limit, and this only in the case where 1.5% 
is outside the other RI limit.
 – Accept criteria similar to validation and transference of RIs 
using small numbers of reference individuals, for sample sizes 
between 30 and 59. Ten percent outside the RIs is found accept-
able as this leaves the probability of false rejection below 6.1%. 
If half or more of the stratifications for one analyte are verified, 
all stratifications are considered verified.
Ethics
The study was a technical and quality investigation in accordance 
with the guidelines of the Northern Denmark Regional Science and 
Ethics Committee.
Results
We performed a preliminary analysis of request patterns 
by identifying outpatients who consulted their general 
practitioners within a period of 2 months and calculated 
the TTPR (Figure 1). Investigating the number of patients 
in each TTPR interval shows that local maxima in the 
number of patients occur at 1, 3, 6 and 12  months, sug-
gesting a significant amount of patients receiving regular 
scheduled follow-up testing (Figure 2A). The apparent 
absence of a local maximum later than 12  months sug-
gests that after 12  months, regular scheduled follow-up 
consultations are rare events. Within each time interval, 
we calculated the percentage of patient results within the 
NORIP RIs (Figure 2B). With decreasing TTPR, we observe 
more patient results falling outside the RIs. The percent-
age of patient results within the RIs seems to be stable in 
the TTPR period >24–18 months, indicating a population 
with homogenous biochemistry. Based on these results, 
we chose 18 months as the cutoff for inclusion of patients 
for verification of RIs. Analysing the results from a single 
reference interval stratification in groups of TTPR was 
done for male creatinine results (Figure 3). This showed 
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that with increasing TTPR, the grouped results became 
more homogeneous, became increasingly normal, and 
contain less outliers, and the indirect determined limits 
approach the NORIP limits.
Using these inclusion criteria, the indirect method 
collected enough results for all tests in 9  weeks. These 
results enabled a possible validation of RIs or verification 
of transference for all RIs with all stratifications (Tables 1 
and 2). Table 1 shows that only the analytes glucose, 
γ-glutamyltransferase, and one stratification of phosphate 
had an increased number of outliers. The remaining tests 
have between 0% and 3.5% outliers. The high number 
for glucose is most likely due to unknown fasting status. 
In general, the method gave results in concordance with 
Serum X verified transfer of NORIP RIs.
In Table 1 part I, RIs were verified by Serum X. Here 19 
of 26 stratifications were verified by the indirect method, 
and all analytes have at least one stratification verified. 
Female stratifications of γ-glutamyltransferase have only 
upper limits verified. Similarly, urate in young females 
and males has only one limit verified. Cholesterol and 
LDL-cholesterol limits are not verified for the age stratifi-
cation ≥50 as well as HDL-cholesterol for females.
The analytes in Table 1 part II were verified by 
Serum X but has zero or only single limits verified by 
the indirect method. For the potassium method, the 
manufacturer states the RI to 3.4–4.5  mmol/L (Roche, 
ISE indirect Na-K-Cl for Gen.2), which is a bit closer to 
the result of the indirect method. In relation to lactate 
dehydrogenase, the level increased by 20–25 U/L upon 
introduction of the transport service of whole blood at 
21 °C. Moreover, as 90% of the included samples arrives 
from the general practitioners via the transport service, 
this effect is clearly seen here. Subtracting the transport 
introduced bias from the CIs brings the indirect method 
close to verifying the NORIP RIs. Upper limits of triglyc-
eride and glucose are as expected difficult to verify as 
the method presented here does not take into account 
if the patient is fasting or not. Lower limits for glucose 
were though verified. For the iron method, the manu-
facturer states the RI to 5.83–34.5 μmol/L (Roche, Iron 
Gen.2), which for the lower limit also is closer to the 
indirect method.
In contrast to parts I and II, part III contains RIs not 
verified by Serum X. The indirect method agrees with this 
on all three tests. Albumin results are clearly under the 
NORIP RIs. We were already aware of this discrepancy and 
published this recently [17]. In our verification, bilirubin 
was found to have a very large imprecision in the lower 
analytical range (<10 μmol/L). This makes it impossible 
to evaluate the lower limit with our instruments. Simi-
larly, it makes it impossible to transfer the RI by use of 
Serum X as the certified value is 8.97 μmol/L. However, 
for our method, the manufacturer states the RI to <21 
μmol/L (Roche, Bilirubin total gen.3). Also for phosphate, 
the transport service of whole blood at 21 °C affected the 
analyte level. The level dropped 0.1  mmol/L upon intro-
duction of the transport service. This decrease has also 
been reported previously in a study from a laboratory uti-
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Figure 3: Histograms of creatinine results for males.
Light grey area covers NORIP RI. Black lines are new calculated RIs 
(95%). Black columns are outliers, grey columns are included in 
the calculation. Each panel outlines calculation in different TTPR 
intervals. Each TTPR panel contains >800 results.
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introduced bias to the CIs brings the indirect method close 
to verifying the NORIP RIs.
Table 1 part IV contains the calcium RI. Serum 
X verified the transfer of the RI, whereas the indirect 
method documents a different RI (Figure 4). In particu-
lar, the lower limit differs with more than acceptable 
bias [19].
Table 2 shows urea. Serum X verified the transfer 
of this RI. The indirect method verifies three of four 
stratifications with ≤10% of the results outside the RI 
to transfer. The fourth stratification is considered veri-
fied as half or more than half of the stratifications are 
verified.
Discussion
Based on the current results, we find that the presented 
indirect method is very useful for verification of RI trans-
ference. Comparing our results to Serum X verification of 
transfer suggests that we can use the TTPR as a surrogate 
for health status. The obvious advantages by this method 
is that all stratifications can be quickly checked and not 
only one stratification as by the CLSI/IFCC method with a 
small number of reference individuals. The only criteria is 
that the algorithm collects preferably >60 results per strati-
fication without outliers. The possible power problem by 
using the CLSI/IFCC method using a small number of refer-
ence individuals is also avoided. This method could verify 
the transfer of albumin RIs as only 9% of all samples are 
outside the RIs in one stratification despite a significant 
bias. The optimal acceptance criteria should approach the 
definition of an RI (2.5% outside the limits on each side). 
To allow some variation, is seem reasonable to use the 
desirable performance goal based on biological variation 
with minimum of 1.4% and a maximum of 4.4% outside 
each RI limit [16]. Modifying this slightly but in concord-
ance with this, we choose 6% as a maximum (sum % ULL 
and % AUL) and a difference of 3% (difference % ULL 
and % AUL). By validation and transference of RIs using 
smaller numbers of reference individuals, it is accepted to 
have up to 10% outside the RIs. It is also accepted to have 
0% outside one or both limits. This happens in situations 
where the proposed limits seem to be too wide, e.g. due 
to increased precision of the new method, or if the tested 
population is more homogenous than the original popula-
tion [3]. Allowing 0% outside one or both limits of course 
increases the risk of accepting too wide limits, especially 
with the sample sizes in some tests in the present study. 
Serum X and the CLSI/IFCC method using a larger number 
of reference individuals do not overcome this problem, as 
both methods use accept criteria based on bias between 
means or to Serum X. Our indirect method is developed for 
validation of RIs to justify transference only. The intentions 
are not to change any limits. However, the indirect method 
does warrant new investigations of some test or test stratifi-
cations. Inspecting some of these cases shows the strengths 
of our approach. Pancreatic amylase RIs were calculated 
to 13–53 U/L. This is exactly similar to the RI supplied by 
the manufacturer (Roche, Pancreas-α-amylase EPS). This 
Table 2: Verification of transference of NORIP RI by a small number 
of results.







Urea, mmol/L   F   18–49  2.6–6.4  54 (2)  5.8  0  X
Urea, mmol/L   F   ≥50  3.1–7.9  46 (2)  0  0  X
Urea, mmol/L   M   18–49  3.2–8.1  55 (0)  7.3  0  X
Urea, mmol/L   M   ≥50  3.5–8.1  31 (3)  17.9  3.6  (X)
n, total number of results; n outlier, number of outliers identified; 
% ULL, % of results (without outliers) under NORIP lower limit; 
% AUL, % of results (without outliers) above NORIP upper limit; 
Verify, X denotes limits verified according to criteria 3; (X) accepted 















Figure 4: Histogram of calcium results.
Light grey area covers NORIP RI. Long lines are calculated RI (95%). 
Short dotted lines are 90% confidence interval for the reference 
limits. Black columns are outliers, grey columns are included in 
the calculation.
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would suggest the use of manufacturer RI instead of NORIP. 
Inspecting magnesium, urate and female stratifications of 
creatinine and γ-glutamyltransferase where either % ULL 
or AUL is 0 or only one limit is verified by CI, it is found 
that the absolute differences are minor. LDL-cholesterol 
(age ≥50) cannot be verified if cholesterol (age ≥50) is not 
verified as it is calculated based on cholesterol. However, 
it could warrant further investigation in the age ≥50 strati-
fication, as it is very close to the 30–49 age stratification. 
For HDL-cholesterol (females), both limits determined by 
the indirect method are lower than the NORIP limits. This 
could be due to the well-known preanalytical factors that 
affect HDL-cholesterol concentrations in females, e.g. preg-
nancy and progestins [20]. The upper limits of young males 
γ-glutamyltransferase and iron are not verified; for this, we 
find no obvious reasons. Possibly all γ-glutamyltransferase 
stratifications could benefit from a longer sampling time 
(larger n, without outliers). In addition to the lower limit 
for iron supplied by the manufacturer, the very low lower 
limit found by the indirect method could also be due to 
inability to exclude some anaemic subjects.
In conclusion, we find our indirect approach useful, 
e.g. for verification of RIs from a manufacturer on a new 
method or for validation of the transference of RI between 
methods even after a short operation time. This is possi-
ble as it uses current test results and only historic request 
patterns without the addition of clinical information. We 
also find our indirect method fit for reviewing or validating 
current RIs [21, 22]. It avoids the obstacles by finding and 
obtaining plasma from reference individuals for the CLSI/
IFCC method. The method is of limited use where informa-
tion about the patients is essential, e.g. fasting in relation 
to lipid status. Using information from all stratifications 
makes it possible to perform a critical review of selected 
RIs. Rejection of RI transference would likely be due to true 
differences between populations or methods. However, 
some differences may arise from other factors, especially 
selection bias and disease prevalence. For instance, tests 
that are not typically ordered on healthy patients may be 
associated with investigation of likely or confirmed disease 
and therefore associated with higher disease prevalence. 
A primary limitation is the prerequisite of an LIS provid-
ing complete request history for each patient in the study 
period. Incomplete patient request history may result in 
the inclusion of unhealthy subjects compromising transfer 
evaluation. Ensuring complete patient request history is not 
trivial but is likely when the LIS covers a large geographical 
area as in this study. With this, we will encourage others to 
investigate their LIS and TTPR for finding their laboratory’s 
subpopulation with the lowest percentage of diseased sub-
jects for verification of RIs by indirect methods.
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